34th Annual - New Treatments in Chronic Liver Disease
This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.
There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies that have been approved and are currently in use. The second will be on the benefits of cure and post-cure management of patients with cirrhosis. In addition, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters.
In this past year, new treatments have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). For this reason, we have invited Dr. Cynthia Levy, Assistant Director of the Schiff Center for Liver Diseases at the University of Miami, Miller School of Medicine to act as our William S. Haubrich Memorial Lecturer on these topics. The course will also review alcoholic liver disease and NASH, which have now surpassed chronic hepatitis C as the leading indications for liver transplantation in the United States. We have invited a world-recognized expert on alcoholic liver disease to update our knowledge of the topic this year.
Although hepatitis B treatments have not changed, we now have more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease will also be included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting, including the first results of a phase 3 global treatment trial. The explosive growth of NASH in the United States has created a significant need for effective drug therapy. A number of new systemic therapies for HCC that have been approved in the last two years will also be discussed. In addition, the course will provide updates on management of hepatic encephalopathy, hyponatremia, thrombocytopenia, and complications in the transplant candidate.